年龄对卵巢癌临床试验入组与耐受性的影响
本研究回顾性分析2000至2013年在本机构入组一线化疗试验的336例卵巢癌患者,按年龄<70岁与≥70岁分组。两组化疗周期数、剂量调整、延迟及毒性发生率相似,但年龄≥70岁、III/IV期和残留病灶独立预测更短总生存。作者认为在医生偏倚去除且化疗耐受性相似的情况下,固有肿瘤生物学可能是重要因素。
要点
- ≥70岁患者占23.5%(79/336),两组化疗完成周期数、剂量调整及延迟无显著差异。
- 年龄≥70岁(HR 1.8,95%CI 1.27-2.54,p=0.0009)独立预测更短总生存。
- III/IV期(HR 3.44,95%CI 1.08-10.95,p=0.036)和残留病灶(HR 2.63,95%CI 1.82-3.78,p<0.0001)也独立预测更短总生存。
核心结论
- 数据支持老年卵巢癌患者生存更短的报告,在医生偏倚去除且化疗耐受性相似的情况下,固有肿瘤生物学可能是重要因素。
- 需要进一步研究以确定年龄对结局造成不平等的机制。
研究设计与样本
- 回顾性队列研究,纳入2000至2013年在本机构入组一线化疗试验的卵巢癌患者336例。
- 按年龄<70岁与≥70岁分组,使用SAS 9.3分析临床、病理和治疗特征。
主要发现
- 336例中79例(23.5%)≥70岁,两组人口学特征相似。
- ≥70岁组与<70岁组完成化疗周期数相当(p=0.16),剂量调整(p=0.40)和延迟(p=0.26)相似。
- 血液学和非血液学毒性发生率相似。
- 年龄≥70岁(HR 1.8,95%CI 1.27-2.54,p=0.0009)、III/IV期(HR 3.44,95%CI 1.08-10.95,p=0.036)和残留病灶(HR 2.63,95%CI 1.82-3.78,p<0.0001)独立预测更短总生存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
- 作者在结论中提出需要进一步研究以确定年龄对结局造成不平等的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Increasing age has been correlated with shorter survival in ovarian cancer patients, a finding attributed to diminished tolerance of standard therapy. Elderly patients, however, are less likely to enroll on clinical trials; thus, limited data exists to evaluate their response to front line treatment. This study describes how elderly patients on trial fared, with respect to toxicity and response, compared to younger women. METHODS: A retrospective cohort study was performed of ovarian cancer patients enrolled in front line chemotherapy trials at our institution between 2000 and 2013. Patients were dichotomized by age: <70 and ≥70years. Clinical, pathologic, and treatment characteristics were recorded and analyzed using SAS version 9.3. RESULTS: 336 patients were enrolled. Of these, 79 (23.5%) were ≥70yrs. Demographics were similar between the two groups. Compared to patients <70, those ≥70 completed a comparable number of chemotherapy cycles (p=0.16) and had similar numbers of dose modifications (p=0.40) and delays (p=0.26). Both hematologic and non-hematologic toxicities occurred at similar rates as well. Age≥70 (HR 1.8, 95% CI 1.27-2.54, p=0.0009), stage III/IV (HR 3.44, 95% CI 1.08-10.95, p=0.036), and residual disease (HR 2.63, 95% CI 1.82-3.78, p<0.0001) were independently predictive of shorter overall survival. CONCLUSION: Our data continues to support reports of shorter survival for older women with ovarian cancer. With physician bias removed and similar chemotherapy tolerance noted, our study suggests that inherent tumor biology may be a significant contributor. Further research is needed to identify the mechanisms which contribute to the inequality that age imposes on outcomes.
引用
- Gillen J, Gunderson C, Greenwade M, et al. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017. PMID: 28087143. doi:10.1016/j.ygyno.2016.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。